Axikin Pharmaceuticals and Proteros Enter into Fragment-Based Lead Discovery Collaboration

Published: Mar 30, 2009

SAN DIEGO, Calif. & MUNICH, Germany--(BUSINESS WIRE)--Axikin Pharmaceuticals (“Axikin”), San Diego, CA, U.S.A. and Proteros fragments (“Proteros”), Munich, Germany, a specialist structure-based lead discovery company, are pleased to announce today that they have entered into a significant research service collaboration to discover novel, customized lead compounds for the treatment of inflammatory diseases.

Back to news